PT  - JOURNAL ARTICLE
AU  - Klaassen, Fayette
AU  - Chitwood, Melanie H.
AU  - Cohen, Ted
AU  - Pitzer, Virginia E.
AU  - Russi, Marcus
AU  - Swartwood, Nicole A.
AU  - Salomon, Joshua A.
AU  - Menzies, Nicolas A.
TI  - Population immunity to SARS-CoV-2 in US states and counties due to infection and vaccination, January 2020-November 2021
AID  - 10.1101/2021.12.23.21268272
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.23.21268272
4099  - http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268272.short
4100  - http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268272.full
AB  - Importance Prior infection and vaccination both contribute to population-level SARS-CoV-2 immunity. Population-level immunity will influence future transmission and disease burden.Objective For each US county and state, we estimated the fraction of the population with prior immunological exposure to SARS-CoV-2 (ever infected with SARS-CoV-2 and/or received one or more doses of a COVID-19 vaccine) as well as the fraction with effective protection against infection and severe disease from prevalent SARS-CoV-2 variants, from January 1st, 2020, to October 31st, 2021.Design, settings, participants We used daily SARS-CoV-2 infection estimates for each US state and county, derived based on reported data on COVID-19 cases and deaths. We collated county-level vaccination coverage data and estimated the fraction of individuals both vaccinated and previously infected using the Census Bureau’s Household Pulse Survey. We used published evidence on natural and vaccine-induced immunity, and how protection wanes over time. We used a Bayesian model to synthesize evidence and estimate population immunity outcomes.Main Outcomes and Measures Primary outcomes were the fraction of the population with (i) a history of exposure to SARS-CoV-2 infection or COVID-19 vaccination or both, (ii) effective protection against infection, and (iii) effective protection against severe disease. We estimated outcomes for each US state and county from January 1st, 2020, to October 31st, 2021.Results The estimated percentage of the US population with a history of SARS-CoV-2 infection or vaccination, as of October 31, 2021, was 86.2% (95%CrI: 82.2%-93.0%), compared to 24.9% (95%CrI: 18.5%-34.1%) on January 1, 2021. State-level estimates for October 31, 2021, ranged between 72.2% (95%CrI: 62.5%-83.3%, West Virginia) and 92.3% (95%CrI: 88.6%-96.1%, Florida). Accounting for waning, the effective protection against infection with prevalent strains as of October 31 was 49.9% (95%CrI: 45.4%-56.6%) nationally and ranged between 37.2% (95%CrI: 33.4%-44.7%, Vermont) and 59.5% (95%CrI: 56.4%-66.0%, Florida). Effective protection against severe disease was 77.4% (95%CrI: 73.7%-83.4%) nationally and ranged between 62.9% (95%CrI: 55.2%-73.3%, West Virginia) and 83.8% (95%CrI: 80.7%-88.0%, Florida).Conclusions and Relevance The fraction of the population with effective protection against SARS-CoV-2 infection and severe COVID-19 varies across the United States, but a substantial proportion of the population remains susceptible.Question How have SARS-CoV-2 infection and COVID-19 vaccination contributed to population-level immunity against SARS-CoV-2 in US states and counties over 2020-2021?Findings The estimated percentage of the US population with effective protection against infections by the prevalent distribution of SARS-CoV-2 variants as of October 31, 2021 was 49.9% (95%CrI: 45.4%-56.6%), and ranged between 37.2% (95%CrI: 33.4%-44.7%, Vermont) and 60.9% (95%CrI: 56.4%-66.0%, Florida) across US states.Meaning Population immunity to SARS-CoV-2 varies across the United States, but a substantial fraction of the population in every state remains susceptible to infection.Competing Interest StatementVEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors have declared that no competing interest exist.Funding StatementVEP reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093 TC reports grants from National Institute of Allergy and Infectious Diseases R01 AI112438 NAM reports grants from National Institute of Allergy and Infectious Diseases R01 AI146555-01A1 JAS reports funding from the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-02) and the National Institute on Drug Abuse (3R37DA01561217S1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in the main analysis are available from The Covid Tracking Project, Johns Hopkins CSSE, Github, US Census Bureau, Ipsos and a JAMA publication. Code for analyses is available from GitHub. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the main analysis are available from The Covid Tracking Project, Johns Hopkins CSSE, Github, US Census Bureau, Ipsos and a JAMA publication. Code for analyses is available from GitHub. https://covidtracking.com/ https://www.mass.gov/info-details/covid-19-response-reporting https://www.openicpsr.org/openicpsr/project/144903/version/V1/view https://github.com/bansallab/vaccinetracking/tree/main/vacc_data https://www.census.gov/programs-surveys/household-pulse-survey/data.html https://github.com/covidestim/covidestim/immunity-waning https://jamanetwork.com/journals/jama/fullarticle/2784013 https://covidtracking.com/ https://www.mass.gov/info-details/covid-19-response-reporting https://www.openicpsr.org/openicpsr/project/144903/version/V1/view https://github.com/bansallab/vaccinetracking/tree/main/vacc_data https://www.census.gov/programs-surveys/household-pulse-survey/data.html https://github.com/covidestim/covidestim/immunity-waning https://jamanetwork.com/journals/jama/fullarticle/2784013